These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22895559)

  • 21. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?
    Hill S; Freemantle N
    Pharmacoeconomics; 2003; 21(11):761-7. PubMed ID: 12859218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. South Australian Medicines Evaluation Panel in review: providing evidence-based guidance on the use of high-cost medicines in the South Australian public health system.
    Lambert R; Burgess N; Hillock N; Gailer J; Hissaria P; Merlin T; Pearson C; Reddi B; Ward M; Hill C
    Aust Health Rev; 2021 Mar; 45(2):207-213. PubMed ID: 33762084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
    Wallerstedt SM; Henriksson M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Essential Medicines in a High Income Country: Essential to Whom?
    Duong M; Moles RJ; Chaar B; Chen TF;
    PLoS One; 2015; 10(12):e0143654. PubMed ID: 26650544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?
    Drummond M
    Pharmacoeconomics; 1992; 1(Suppl 1):61-9. PubMed ID: 10146934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of the 'linked evidence approach' to guide policy on the reimbursement of personalized medicines.
    Merlin T
    Per Med; 2014 Jun; 11(4):435-448. PubMed ID: 29783477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing Data Sources for Medicine Price Studies.
    Vogler S; Schneider P
    Int J Technol Assess Health Care; 2019 Jan; 35(2):106-115. PubMed ID: 30922418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Companion diagnostics and reimbursement system].
    Tazawa Y
    Rinsho Byori; 2013 May; 61(5):435-42. PubMed ID: 23947184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
    Hailey D
    Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individual health services.
    Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
    GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
    Seo MK; Cairns J
    BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness guidelines. The experience of Australian manufacturers.
    Gorham P
    Pharmacoeconomics; 1995 Nov; 8(5):369-73. PubMed ID: 10160071
    [No Abstract]   [Full Text] [Related]  

  • 38. Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.
    Lewis JR; Kerridge I; Lipworth W
    J Clin Oncol; 2015 Dec; 33(34):4112-7. PubMed ID: 26460298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Payer view of personalized medicine.
    Pezalla EJ
    Am J Health Syst Pharm; 2016 Dec; 73(23):2007-2012. PubMed ID: 27864208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.
    Phillips KA; Douglas MP; Trosman JR; Marshall DA
    Value Health; 2017 Jan; 20(1):47-53. PubMed ID: 28212968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.